TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30080229
Drug: Investigational product
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product (Cerbella TM) consisting of an emulsified liquid combination of standardized fish oil, panax ginseng extract, and green tea catechins
Study: 26950257
Drug: Audio-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audio-based cognitive-behavioural therapy (CBT) program
Study: 7827929
Drug: Ranitidine 100
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 100 mg IV twice daily for 4 days, followed by 150 mg orally twice daily for 5 days
Study: 26667739
Drug: 40 ml/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml/day of extra virgin coconut oil
Study: 23315144
Drug: Tibolone (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (various doses)
Study: 21252731
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (cord clamping for 30 seconds)
Study: 11822785
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg clodronate
Study: 31891746
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg resveratrol
Study: 27594544
Drug: Suicide prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suicide prevention program (twice a week for 5 weeks)
Study: 26999890
Drug: Mini-implants (MI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-implants (MI)
Study: 24459173
Drug: Prehab (exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehab (exercise and education classes for 60 minutes/day, twice weekly for at least four weeks)
Study: 18818954
Drug: Ceftibuten 9
Normalized name: ceftibuten 90 MG in 5 mL Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten 9 mg/kg once daily for 10 days
Study: 18818954
Drug: TMP‐SMX (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP‐SMX (3 mg + 15 mg)/kg twice daily for 10 days
Study: 15450766
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol 100 ml IV in 20 min
Study: 15450766
Drug: Sham infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham infusion (control)
Study: 8015241
Drug: Maxaquin 400
Normalized name: Maxaquin 400mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxaquin 400 mg once a day for 7-14 days
Study: 8015241
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice a day for 7-14 days
Study: 71970
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg flurbiprofen daily (tablet or liquid suspension)
Study: 31165663
Drug: Ticagrelor (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (90 mg BID for 30 days)
Study: 21382172
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg loading dose)
Study: 31165663
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg OD for 30 days)
Study: 25922838
Drug: Long protocol
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long protocol with combined oral contraceptive (OC) pills
Study: 25922838
Drug: Short agonist
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short agonist protocol with estradiol priming
Study: 21748205
Drug: 0.1 mcg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mcg/kg/min remifentanil infusion (Group R1)
Study: 21748205
Drug: 0.15 mcg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mcg/kg/min remifentanil infusion (Group R2)
Study: 19523012
Drug: Diphenhydramine (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (i.v. microdose 0.1 mg)
Study: 19523012
Drug: Diphenhydramine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (oral microdose 0.1 mg)
Study: 19523012
Drug: NBI‐2 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI‐2 (oral microdose 0.1 mg)
Study: 19523012
Drug: NBI‐1 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI‐1 (oral microdose 0.1 mg)
Study: 19523012
Drug: NBI‐3 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI‐3 (oral microdose 0.1 mg)
Study: 19523012
Drug: NBI‐4 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI‐4 (oral microdose 0.1 mg)
Study: 19523012
Drug: NBI‐4 (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI‐4 (i.v. microdose 0.1 mg)
Study: 19523012
Drug: NBI‐1 (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI‐1 (i.v. microdose 0.1 mg)
Study: 19523012
Drug: NBI‐3 (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI‐3 (i.v. microdose 0.1 mg)
Study: 19523012
Drug: NBI‐2 (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI‐2 (i.v. microdose 0.1 mg)
Study: 16951472
Drug: PTH and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH and raloxifene (combined treatment)
Study: 12730811
Drug: Water soluble
Normalized name: WATER SOLUBLE BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water soluble vitamin E (100 mg)
Study: 2009249
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (beta-blockers or diuretics)
Study: 7074750
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg every 6 hours
Study: 7074750
Drug: Metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50 mg every 6 hours
Study: 7074750
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg every 6 hours
Study: 31732852
Drug: Topical saliva
Normalized name: Dunaliella salina extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical saliva gel (GC)
Study: 28844754
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone enanthate 2 mg/kg (group 2b)
Study: 25909311
Drug: Transfusion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion with hemoglobin concentrations maintained above 9.0 g/dL (Group Hb9)
Study: 25909311
Drug: Withholding transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding transfusion unless hemoglobin fell below 7.0 g/dL (Group Hb7)
Study: 23009800
Drug: Educational slides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational slides about treatment for AUD
Study: 19919580
Drug: Intrarectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal lidocaine gel (10 ml of 2% lidocaine)
Study: 19919580
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block (20 ml 0.1% bupivacaine with 75 microg fentanyl)
Study: 19042837
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg octreotide
Study: 19042837
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg hyoscine hydrobromide
Study: 12547870
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care treatment (control)
Study: 10883420
Drug: Melatonin 2
Normalized name: melatonin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 2 mg intravenously
Study: 10883420
Drug: Melatonin 2
Normalized name: melatonin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 2 mg orally
Study: 10883420
Drug: Melatonin 4
Normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 4 mg orally
Study: 9535618
Drug: Chronic nitrate
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic nitrate therapy
Study: 22355040
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg/100 ml)
Study: 19116709
Drug: Glycopyrronium bromide
Normalized name: Glycopyrronium bromide
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glycopyrronium bromide 0.4 mg every 6 hours for 12 hours
Study: 19116709
Drug: Scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine hydrobromide 0.5 mg every 6 hours for 12 hours
Study: 12821477
Drug: Garenoxacin 100
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Garenoxacin 100 mg
Study: 12821477
Drug: Garenoxacin 1200
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Garenoxacin 1200 mg
Study: 12821477
Drug: Garenoxacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garenoxacin (100 to 400 mg)
Study: 12821477
Drug: Garenoxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garenoxacin (400 mg and above)
Study: 12821477
Drug: Garenoxacin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garenoxacin (all doses)
Study: 8934255
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the amount of LH administered
Study: 8934255
Drug: Standard amount
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard amount of LH administered
Study: 1766100
Drug: Midazolam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.05 mg.kg‐1), n = 6
Study: 1766100
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg.kg‐1), n = 7
Study: 6350615
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative antibiotics
Study: 29172593
Drug: Internet-delivered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive-behavioral therapy (iCBT) program for health anxiety (n = 45)
Study: 6832462
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg indobufen administered orally or by i.v. injection
Study: 28758526
Drug: Oral Reading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Reading Fluency (ORF) slope
Study: 18069601
Drug: Antithrombotic therapies
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapies for stroke prevention
Study: 18069601
Drug: Rate control
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate control drugs (old and new)
Study: 16096180
Drug: 0.03% or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% or 0.1% tacrolimus ointment applied twice daily
Study: 12030342
Drug: Nicorandil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (3 mg/h infusion)
Study: 12799953
Drug: Butylscopolamine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butylscopolamine 20 mg
Study: 7516295
Drug: Human, recombinant
Normalized name: Erythropoietin (human, recombinant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human, recombinant GH (Genotropin, Kabi Pharmacia, Uppsala, Sweden) at a dosage of 0.1 IU/kg body weight per day
Study: 2680176
Drug: Oral photochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral photochemotherapy (PUVA) for 4 weeks
Study: 7305656
Drug: Propranolol hydrochloride
Normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol hydrochloride therapy after surgery
Study: 7305656
Drug: No propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: No propranolol hydrochloride therapy after surgery
Study: 22175695
Drug: Water treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water treatment and hygiene promotion (WT & HP)
Study: 22175695
Drug: Sanitation improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sanitation improvement in combination with WT & HP
Study: 16211739
Drug: Granisetron 0.2
Normalized name: granisetron 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 0.2 mg
Study: 16211739
Drug: Granisetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 0.3 mg
Study: 16211739
Drug: Granisetron (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (all doses)
Study: 12423702
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogens
Study: 12423702
Drug: Transdermal estradiol‐17‐beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estradiol‐17‐beta with progestins
Study: 10606212
Drug: Calcium HMB
Normalized name: calcium HMB/vitamin D3 0.5 gram-2.08 mcg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium HMB supplementation (3 to 6 g x d(‐1))
Study: 1747493
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg tid)
Study: 1747493
Drug: Clebopride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clebopride (0.5 mg tid)
Study: 26565438
Drug: Hybrid Constraint
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid Constraint Induced Movement Therapy (hCIMT)
Study: 26565438
Drug: Distributed individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distributed individual occupational therapy (OT)
Study: 23852397
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus weekly split-dose cisplatin (SWP)
Study: 23852397
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus standard-dose cisplatin (SP)
Study: 23065071
Drug: Low-dose tricyclic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tricyclic antidepressants
Study: 17708846
Drug: Glutamine treatment
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine treatment group (0.4 g/kg per day for 7 days)
Study: 12776266
Drug: Long daily
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long daily regimen (prednisolone 60 mg/m2 for 6 weeks, then 40 mg/m2 alternate-day for 6 weeks)
Study: 12776266
Drug: Long alternate-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long alternate-day regimen (prednisolone 60 mg/m2 for 4 weeks, then 60 mg/m2 alternate-day for 4 weeks, tapering by 10 mg/m2 every 4 weeks)
Study: 10367871
Drug: Oral contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contrast solution (OC)
Study: 10367871
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral contrast solution (no OC)
Study: 8566682
Drug: CBS 480
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS 480 mg daily during 6 weeks
Study: 8566682
Drug: M 1
Normalized name: CRM 197
DrugBank: Corynebacterium diphtheriae CRM197 protein (DB16712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M 1 g daily during 6 weeks
Study: 8566682
Drug: CBS 480
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS 480 mg daily plus M 750 mg daily during 4 weeks
Study: 8566682
Drug: CBS 480
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS 480 mg daily plus Amoxycillin 1500 mg daily during 4 weeks
Study: 8566682
Drug: M 750
Normalized name: aniracetam 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: M 750 mg daily plus Amoxycillin 1500 mg daily during 4 weeks
Study: 2166253
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 mg/die
Study: 2166253
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg/die
Study: 2166253
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg/die
Study: 2166253
Drug: Quinapril 40
Normalized name: quinapril 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 40 mg/die
Study: 7428405
Drug: Sustained-release clonidine
Normalized name: clonidine Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release clonidine (250 or 500 micrograms/day)
Study: 7428405
Drug: Standard tablet
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tablet clonidine (300 or 450 micrograms/day)
Study: 7428405
Drug: Sustained-release clonidine
Normalized name: clonidine Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release clonidine
Study: 30103252
Drug: Oral apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral apixaban (10 mg twice daily for the first 7 days, then 5 mg twice daily)
Study: 30103252
Drug: Subcutaneous dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dalteparin (200 IU/kg for the first month, then 150 IU/kg once daily)
Study: 22739038
Drug: 1% diquafosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% diquafosol ophthalmic solution
Study: 22739038
Drug: 1% and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% and 3% diquafosol ophthalmic solutions
Study: 15753792
Drug: Thyroglobulin (Tg)
Normalized name: thyroglobulin
DrugBank: Thyroglobulin (DB01584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroglobulin (Tg) measurement <2 ng/ml
Study: 15753792
Drug: Ablation dose
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablation dose (AD)
Study: 11965203
Drug: Thrombolysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis with aspirin
Study: 27535131
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) group-based enhancement to home visiting (HV/CBT)
Study: 16776752
Drug: Intensive mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive mixture therapy (IMT) using insulin lispro mixture 50/50 before breakfast and lunch and insulin lispro mixture 25/75 before dinner
Study: 16776752
Drug: Intensive mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive mixture therapy (IMT)
Study: 11426092
Drug: Dihydroergotamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine 0.25 mg intravenously
Study: 9431382
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of DTaP, hepatitis B vaccine, and PRP-T vaccine
Study: 9431382
Drug: Combination DTaP-hepatitis
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination DTaP-hepatitis B vaccine-PRP-T
Study: 9431382
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of CRM197-OS
Study: 7032489
Drug: Injection
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: 21125466
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion 80 mmol/day
Study: 15053497
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment program including fines, community service, monetary restitution, written essays, anti-shoplifting videos, apology letters, and individual and/or family counseling
Study: 15053497
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment program
Study: 8882238
Drug: Midazolam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (5 mg.70 kg‐1 bolus at induction followed by 1 mg.70 kg‐1.h‐1 continuous infusion for 48 h)
Study: 6613138
Drug: High-dose irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose irradiation of 40 to 66 Gy (59 cases)
Study: 6613138
Drug: Simultaneous irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous irradiation and COMP chemotherapy (80 cases including 30 survivors)
Study: 30813934
Drug: Intramuscular 17-alpha
Normalized name: 17-alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 17-alpha hydroxprogesterone caproate (17P)
Study: 21822678
Drug: Habitual diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habitual diet plus additional food supplement (SUP, n=15)
Study: 15339761
Drug: Duloxetine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 80 mg/d for 4 weeks, escalated to 120 mg/d for 4 weeks
Study: 9138335
Drug: Citarabine (standard,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citarabine (standard, intermediate or high doses) combined with daunomicin or mitoxantrone
Study: 2476604
Drug: Potassium supplements
Normalized name: POTASSIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium supplements (64 mmol daily)
Study: 27330154
Drug: Intact hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact hydrocodone ER 45-mg tablet
Study: 27330154
Drug: Finely crushed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finely crushed hydrocodone ER 45-mg tablet
Study: 27330154
Drug: Hydrocodone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone IR 45-mg powder
Study: 24816760
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of tranexamic acid (TXA) 500 mg in 20 mL of normal saline solution, applied into the joint for 5 min at the end of surgery.
Study: 24816760
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received an equivalent volume of normal saline solution, applied into the joint for 5 min at the end of surgery.
Study: 19736249
Drug: Psychiatric examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychiatric examination including diagnostics with Present State Examination and feedback regarding treatment and rehabilitation; 329 (78.3%) participated in the intervention.
Study: 16893434
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg-simvastatin 20 mg